Subscribe
FDA updates sotatercept-csrk label with HYPERION data, showing earlier use cuts PAH clinical worsening risk 76% alongside background therapy.
7 Drugs Approved for Primary Care: Q2 2026
FDA-Approved Baxdrostat Adds New Mechanism for Uncontrolled Hypertension
Is Baxdrostat the Missing Link in Hypertension Treatment? With Payal Kohli, MD
FDA Approves Baxdrostat for Uncontrolled Hypertension on Background Therapy
Kamel Abou Hussein, MD; Sushil Bhardwaj, MD, FACP
Neil M. Iyengar, MD; Swati Vishwanathan, MD
1 Session is Available!
3 Sessions are Available!
Sarah M. Tolaney, MD, MPH; Yelda Nouri, MD
Daniela A. Bota, MD, PhD; Maya Hrachova, DO
Geoffrey Ku, MD; Girish Kunapareddy, MD
2 Sessions are Available!
Jonathan Barratt, PhD, FRCP; Brendon L. Neuen, MBBS, PhD, MSc
Tiffany A. Traina, MD, FASCO; Nour Abuhadra, MD; Joshua Z. Drago, MD, MS; Ruth O’Regan, MD; Vered Stearns, MD, FASCO; Neil Vasan, MD, PhD; Anna Weiss, MD
Shubham Pant, MD, MBBS; Alison Schram, MD; Helena Yu, MD
Ilan Melnick, MD; Linda Collado, MD, DABPN, FAPA; Maria Collado, MD, FAPA
Dilsher S. Dhoot, MD, FASRS
Deep Parikh, MD
Matthew Heeney, MD; Biree Andemariam, MD
Mile Brujic, OD, FAAO; Pierce Kenworthy, OD, FAAO; Blair Lonsberry, MS, OD, MEd, FAAO
James F. Howard Jr, MD, FAAN; Tuan Vu, MD